These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15757463)

  • 1. Ocular bacterial infections: current and future treatment options.
    Kowalski RP; Dhaliwal DK
    Expert Rev Anti Infect Ther; 2005 Feb; 3(1):131-9. PubMed ID: 15757463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic resistance in ocular bacterial pathogens.
    Sharma S
    Indian J Med Microbiol; 2011; 29(3):218-22. PubMed ID: 21860100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A primer on topical antibiotics for the skin and eyes.
    Noah S
    J Drugs Dermatol; 2008 Apr; 7(4):409-15. PubMed ID: 18459527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
    Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ocular bacterial infections: an update.
    Hammond RW; Edmondson W
    J Am Optom Assoc; 1997 Mar; 68(3):178-87. PubMed ID: 9109296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.
    Asbell PA; Sahm DF; Shaw M; Draghi DC; Brown NP
    J Cataract Refract Surg; 2008 May; 34(5):814-8. PubMed ID: 18471638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriological findings in patients with ocular infection and antibiotic susceptibility patterns of isolated pathogens.
    Khosravi AD; Mehdinejad M; Heidari M
    Singapore Med J; 2007 Aug; 48(8):741-3. PubMed ID: 17657382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of moxifloxacin as shown in animal and in vitro studies.
    McGee DH; Holt WF; Kastner PR; Rice RL
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to ocular antibiotics: an overview.
    Brown L
    Clin Exp Optom; 2007 Jul; 90(4):258-62. PubMed ID: 17535364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious disease: changing antibiotic susceptibility.
    Kowalski RP; Karenchak LM; Romanowski EG
    Ophthalmol Clin North Am; 2003 Mar; 16(1):1-9. PubMed ID: 12683244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of Listeria monocytogenes keratitis to respond to topical ofloxacin.
    Altaie R; Fahy GT; Cormican M
    Cornea; 2006 Aug; 25(7):849-50. PubMed ID: 17068464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial agents for ocular therapeutics.
    Kern TJ
    Vet Clin North Am Small Anim Pract; 2004 May; 34(3):655-68. PubMed ID: 15110977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of Staphylococci isolated from naturally occurring canine external ocular diseases.
    Varges R; Penna B; Martins G; Martins R; Lilenbaum W
    Vet Ophthalmol; 2009; 12(4):216-20. PubMed ID: 19604336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The microbiology of the eye.
    Armstrong RA
    Ophthalmic Physiol Opt; 2000 Nov; 20(6):429-41. PubMed ID: 11127123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fourth-generation fluoroquinolone-resistant bacterial keratitis.
    Jhanji V; Sharma N; Satpathy G; Titiyal J
    J Cataract Refract Surg; 2007 Aug; 33(8):1488-9. PubMed ID: 17662450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bioavailability of antibiotics].
    Robert PY; Tassy A
    J Fr Ophtalmol; 2000 May; 23(5):510-3; quiz 523. PubMed ID: 10844315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
    Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Blondeau J
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S64-7. PubMed ID: 16257312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Alfonso E
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of bacterial isolates from corneal specimens and their antibiotic resistance profile.
    Begum NN; Al-Khattaf AS; Al-Mansouri SM; Yeboah EA; Kambal AM
    Saudi Med J; 2006 Jan; 27(1):41-5. PubMed ID: 16432592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.